Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
1.
Rev. Urug. med. Interna ; 8(3)dic. 2023.
Artigo em Espanhol | LILACS-Express | LILACS | ID: biblio-1521627

RESUMO

Introducción: Los pacientes portadores de enfermedades autoinmunes sistemas constituyen una población vulnerable para el desarrollo de infección por COVID-19. Objetivo: Determinar la frecuencia de infección por COVID-19 en los pacientes asistidos en la policlínica, su severidad y su relación con el tratamiento inmunosupresor. Conocer el número de brotes y la tasa de vacunación de nuestra población. Metodología: Estudio transversal de pacientes asistidos en una unidad de enfermedades autoinmunes sistémicas en el período abril 2020-julio 2021. Resultados: Se analizaron 59 pacientes, 19 tuvieron brote de la enfermedad en el último año. 12 tuvieron infección por COVID-19, uno ingresó a cuidados moderados. La mediana de edad de los pacientes infectados fue de 35 años. 55 recibieron vacunación completa. Conclusiones: No se encontró una asociación entre la infección por COVID-19 y brotes de la enfermedad así como tampoco una mayor tasa de hospitalización ni muerte. Los pacientes con Lupus fueron los más vulnerables. La tasa de controles media (presencial/telefónica) fue alta para la totalidad de la población así como la tasa de vacunación.


Introduction: Patients with autoimmune system diseases constitute a vulnerable population for the development of SARS-CoV-2 infection. Objectives: To determine the incidence of SARS-CoV-2 infection in patients seen at the polyclinic. Methodology: Cross-sectional study patients assisted in an autoinmune disease center in the period April 2020-July 2021. Results: 59 patients were analyzed, 19 had flares of the disease in the last year. 12 had SARS CoV-2 infection, 1 was admitted to moderate care. The median age of infected patients was 35 years. 55 received full vaccination. Conclusions: No association was found between COVID-19 infection and diseases flares as well as an increased rate of hospitalization or death. Lupus patients were the most vulnerable. The controls rate (face-to-face/telephone) was high for the entire population as well as the vaccination rate.


Introdução: Pacientes com doenças autoimunes constituem uma população vulnerável ao desenvolvimento da infecção por COVID-19. Objetivo: Determinar a frequência da infecção por COVID-19 em pacientes atendidos na policlínica, sua gravidade e sua relação com o tratamento imunossupressor. Conheça o número de surtos e a taxa de vacinação da nossa população. Metodologia: Estudo transversal. Apresenta 59 pacientes atendidos em unidade EAS no período de abril de 2020 a julho de 2021. Resultados: Foram analisados ​​59 pacientes, 19 tiveram surto da doença no último ano. 12 tiveram infecção por COVID-19, 1 foi internado em cuidados moderados. A idade média dos pacientes infectados foi de 35 anos. 55 receberam vacinação completa. Conclusões: não foi encontrada associação entre infecção por covid-19 e surtos da doença, nem maior taxa de hospitalização ou morte. Pacientes com lúpus eram os mais vulneráveis. A taxa média de controlo (presencial/telefone) foi elevada para toda a população, bem como a taxa de vacinação.

2.
Adv Rheumatol ; 63: 38, 2023. tab, graf
Artigo em Inglês | LILACS-Express | LILACS | ID: biblio-1505594

RESUMO

Abstract Objective To determine prevalence and factors associated with flares post Coronavirus disease 2019 (COVID-19) mRNA vaccination in patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA) and spondyloarthritis (SpA). Methods A retrospective multi-centre study was conducted (January 2021 to February 2022). Data were collected during index visit, defined as first post-vaccine visit in which the patient had a physician-defined flare, or if at least 3 months had elapsed since first vaccine dose, whichever came first. Factors associated with flares were identified using mixed effects Cox regression and expressed as hazard ratio (HR) and 95% confidence interval (CI). Results Total of 2377 patients were included (1563 RA, 415 PsA and 399 SpA). Among patients with RA, PsA and SpA, 21.3%, 24.1% and 21.8% experienced a flare respectively. Of those who experienced a flare, only 10.2%, 11.0% and 14.9% were severe in patients with RA, PsA and SpA respectively. Patients with low or moderate/high disease were more likely to flare compared to those in remission in patients with RA only (HR: 1.68, 95% CI 1.22-2.31; HR: 2.28, 95% CI 1.50-3.48, respectively). Receiving the Moderna vaccine was associated with a higher HR of flare compared to the Pfizer vaccine in patients with PsA only (HR: 2.21, 95% CI 1.20-4.08). Patients who had two vaccine doses were found to be less likely to flare (HR: 0.08, 95% CI 0.06-0.10). HRs of flares were not significantly different among RA, PsA and SpA. Conclusion About one-fifth of patients experienced a disease flare post COVID-19 mRNA vaccination, but most flares were non-severe. Patients with active disease prior to vaccination should be monitored closely for disease flares, especially in patients with RA.

3.
Artigo | IMSEAR | ID: sea-213973

RESUMO

Background:The impact of gas flaring in Ubeji metropolis, relative to other communities of Delta is of interest. This study assessed the environmental impact of gas flaring in Ubeji metropolis of Delta State. The objective of this study is to study the comparative assessment of the environmental impacts of gas flaring on five communities of unequal distance from gas flaring site. Methods:Questionnaire survey was used to evaluate three research questions that included the level of knowledge in the survey communities regarding health impact of gas flaring; prevalence level of assessed health conditions in Ubeji metropolis relative to communities farther from or nearer to Warri gas flaring site; and perceived impact of gas flaring on air quality indicated by health and environmental toxicity indices.Results:Descriptive evaluation of data shows Ubeji appears to have the highest proportion of persons suffering respiratory problems, but the figure for family members is less than some other communities. The respondents nearer flaring site show more awareness compared to those farther away. Critical evaluation showed no directional change in prevalence of disease linked to gas flaring. There is linear relationship between „distance to gas flare site‟ and „toxic impact on air quality‟.Conclusions:This report submits further data to the discourse that, on the basis of nearness to gas flaring site, there is significant difference between communities experience of environmental and health impact.

4.
Chinese Journal of Hepatology ; (12): 261-266, 2019.
Artigo em Chinês | WPRIM | ID: wpr-805048

RESUMO

Objective@#To observe the changes of liver function, virology and serology and the safety of drug withdrawal in pregnant women who are chronic hepatitis B virus (HBV) carriers.@*Methods@#A prospective clinical cohort was established to enroll pregnant women who are chronic HBV carriers and they were divided into the nucleoside/nucleotide analogs (NAs) intervention group and the non-NAs intervention group according to patients' wishes. Liver function, HBV DNA and HBV serological markers were detected at gestation, postpartum 6 weeks, 12 weeks, 24 weeks, 36 weeks and 48 weeks.@*Results@#351 patients were enrolled, 320 in the NAs intervention group and 31 in the non-NAs intervention group. The proportion of postpartum hepatitis flares in both groups was higher than that in pregnancy (39.4% vs 12.5%, P < 0.001; 38.7% vs 3.2%, P = 0.001). Six weeks postpartum was the peak period of hepatitis flares, and 96.0% (121/126) of the hepatitis flares occurred within 24 weeks postpartum. At 6 weeks postpartum, there were 6 cases of alanine aminotransferase (ALT) ≥ 10 times upper limit of normal (ULN) in the NAs intervention group. The rate of the hepatitis flare after drug withdrawal was 16.7% (34/203).@*Conclusion@#Regardless of the presence or absence of NAs intervention, pregnant women who are chronic HBV carriers have a certain proportion of hepatitis flares during pregnancy and postpartum, and the hepatitis flare even have a tendency to be severe. Therefore, drug withdrawal after delivery is not always safe, which requires close observation and classification. At 6 weeks postpartum, the incidence of hepatitis flares was high, and those who meet the treatment indications can get better therapeutic effects if given appropriate treatment. The vast majority (96%) of postpartum hepatitis flares occur within 24 weeks, so it is recommended to follow up to at least 24 weeks postpartum after discontinuation.

5.
Invest. clín ; 57(3): 237-245, Sept. 2016. ilus, graf
Artigo em Espanhol | LILACS | ID: biblio-841114

RESUMO

El propósito del presente estudio fue determinar la relación entre los valores de prolactina sérica y las características clínicas de pacientes con lupus eritematoso sistémico (LES) asistentes a la consulta de Reumatología del Servicio Autónomo Hospital Universitario de Maracaibo, en Maracaibo, Venezuela. Se realizó un estudio descriptivo, correlacional y transversal en pacientes femeninas, mayores de 18 años, con diagnóstico de LES, quienes asistieron al Hospital Universitario de Maracaibo, durante los meses de noviembre 2012 a junio del 2013; se les realizó una historia clínica integral, basada en anamnesis y examen físico, con énfasis en la búsqueda de manifestaciones clínicas de actividad lúpica y se tomaron muestras sanguíneas para la determinación de las concentraciones séricas de prolactina, en el momento de la evaluación de la paciente. Se utilizaron como rangos normales, valores entre 2,1 y 25 ng/mL. La población consistió en un total de 50 pacientes y se clasificó en dos grupos: el primer grupo conformado por 28 mujeres con crisis lúpica y el segundo por 22 sin crisis al momento del estudio. La concentración promedio de prolactina sérica fue de 39,0 ± 59,5 ng/dL para el primer grupo y de 14,2 ± 7,2 ng/dL para el segundo grupo, con diferencias estadísticamente significativas (p=0,044). Las pacientes con crisis lúpica presentaron valores de prolactina más elevados que las pacientes en remisión, no obstante que solo la séptima parte de ellas tenían cifras de prolactina fuera del rango normal. Todas las pacientes asintomáticas presentaron niveles normales de prolactina, por el contrario, todas las pacientes con hiperprolactinemia estaban en crisis lúpica.


To determine the relationship between hyperprolactinemia levels and clinical features of patients with systemic lupus erythematosus (SLE), a descriptive, correlational and cross-sectional study, was performed in female patients over 18 years old, who attended the Rheumatology Clinic at the Hospital Universitario, in Maracaibo, Venezuela, from November 2012 to June 2013. They underwent a comprehensive medical history evaluation, based on interviews and physical examination, with emphasis on the search for clinical manifestations of lupus activity. Blood samples were taken in order to determine prolactin levels at the moment of the patient evaluation. Values from 2.1 to 47.6 ng/mL were considered as normal. The population was classified into two groups: a group formed by 28 women with lupus crisis and another group formed by 22 patients without crisis. The average prolactin serum level was 39.0 ± 59.5 ng/dL for the first group and 14.2 ± 7.2 ng/dL for the second group, indicating statistical significance (p = 0.044). Patients with lupus crisis had prolactin values higher than those of asymptomatic patients, although only oneseventh of them had absolute hyperprolactinemia. All asymptomatic patients had normal levels of prolactin. All patients with hyperprolactinemia were in lupus crisis.


Assuntos
Adulto , Feminino , Humanos , Prolactina/sangue , Lúpus Eritematoso Sistêmico/sangue , Estudos Transversais , Lúpus Eritematoso Sistêmico/diagnóstico
6.
Journal of Korean Medical Science ; : 240-244, 2015.
Artigo em Inglês | WPRIM | ID: wpr-223788

RESUMO

The object of this study was to evaluate the seasonality of gout in Korea. We retrospectively examined data from 330 patients seen at nine rheumatology clinics, treated with urate lowering therapy (ULT) more than one year after stopping prophylactic medication. Demographic data, clinical and laboratory features, and seasonality of gout onset and flares were collected. Season was classified in three-month intervals. The mean age was 52.2 yr and mean disease duration was 26.8 months. The male to female count was 318:12. The onset of acute gouty attacks was obtained in 256 patients. Gout developed most commonly in summer season (36.7%) (P<0.001) and in June (15.6%, P=0.002). During ULT, there were 147 (male 97.3%) gout flares. Although there was no statistically significant difference, gout flares were more common in summer (30.6%). Aggravating factors were identified in 57 flares: alcohol (72.0%) was most common. In the patients who attained target serum uric acid (<6 mg/dL) at the end of prophylaxis, gout flares were high in fall (35.8%) and September (17.0%). In Korea, the summer is most common season of gout onset and there is a tendency for gout flares to increase during ULT in summer/fall season.


Assuntos
Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Consumo de Bebidas Alcoólicas , Artrite Gotosa/tratamento farmacológico , Pressão Sanguínea , Índice de Massa Corporal , Comorbidade , Supressores da Gota/uso terapêutico , Lipídeos/sangue , Proteinúria , República da Coreia/epidemiologia , Estudos Retrospectivos , Estações do Ano , Exacerbação dos Sintomas , Ácido Úrico/sangue
7.
Gut and Liver ; : 661-667, 2013.
Artigo em Inglês | WPRIM | ID: wpr-162813

RESUMO

BACKGROUND/AIMS: Seasonal variation may influence the development and exacerbation of inflammatory bowel disease (IBD). However, most epidemiologic studies on this topic have been conducted in Western countries. The purpose of this study was to determine whether birth dates and symptom flares follow a seasonal pattern in Korean patients with IBD. METHODS: Patients with a diagnosis of IBD established between January 2003 and December 2010 were investigated at six university hospitals in Korea. The expected births and flares, with a uniform distribution during the year and considering differences in the number of days in the months of 1 year, were calculated. RESULTS: A total of 411 patients with ulcerative colitis (UC) and 316 patients with Crohn disease (CD) were included in the study. Birth during the winter period, and especially in January and February, was associated with an increased risk of IBD, especially in UC patients. The symptom flares of CD patients occurred most frequently in the spring, with a nadir in the autumn. However, no disease flare seasonality was noted for UC patients. CONCLUSIONS: Our data suggest that seasonally varying environmental factors during pregnancy and the postpartum period are associated with a susceptibility to IBD later in life and that exacerbations of CD are influenced by seasonal factors.


Assuntos
Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Adulto Jovem , Povo Asiático/estatística & dados numéricos , Colite Ulcerativa/epidemiologia , Doença de Crohn/epidemiologia , Recidiva , República da Coreia/epidemiologia , Estudos Retrospectivos , Fatores de Risco , Estações do Ano , Estatísticas Vitais
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA